Overview

Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

Status:
Completed
Trial end date:
2018-08-10
Target enrollment:
Participant gender:
Summary
This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.
Phase:
Phase 3
Details
Lead Sponsor:
BioQ Pharma, Inc.
Collaborator:
Health Decisions
Treatments:
Ropivacaine